Company Description
Flora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide.
It operates through three segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals. The company cultivates, processes, and supplies medicinal-grade cannabis flower, and cannabis derived medical and wellness products.
It also offers food and beverage, nutraceuticals, cannabis accessories and technology, personal care, and wellness; cannabidiol (CBD) derived products, such as gummies, topicals, tinctures, and vape products; cannabis consumption accessories, personal storage, and travel accessories for the vape and dry herbs.
In addition, the company manufactures and distributes pharmaceutical goods and medical cannabis products to treat a variety of health indications, including drugs related to cancer therapies, attention-deficit/hyperactivity disorder, multiple sclerosis, and anti-depressants.
The company sells its products under the JustCBD, Vessel, and Phatebo brands. Flora Growth Corp. was incorporated in 2019 and is based in Fort Lauderdale, Florida.
Country | United States |
Founded | 2019 |
IPO Date | May 11, 2021 |
Industry | Drug Manufacturers - Specialty & Generic |
Sector | Healthcare |
Employees | 108 |
CEO | Clifford Starke |
Contact Details
Address: 3406 SW 26th Terrace, Suite C-1 Fort Lauderdale, Florida 33132 United States | |
Phone | 954 842 4989 |
Website | floragrowth.com |
Stock Details
Ticker Symbol | FLGC |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $5.00 |
CIK Code | 0001790169 |
CUSIP Number | 339764102 |
ISIN Number | CA3397642016 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Clifford A. Starke | Chief Executive Officer and Director |
Dany Vaiman | Chief Financial Officer |
Samuel Dorf Esq. | Executive Chairman of the Board |
Dr. Manfred Ziegler | Managing Director |
Patrick Moloney | Head of Product Development |
Aaron Atin | Corporate Secretary |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 28, 2025 | EFFECT | Notice of Effectiveness |
Mar 25, 2025 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
Mar 24, 2025 | 10-K | Annual Report |
Feb 28, 2025 | 8-K | Current Report |
Feb 24, 2025 | S-3 | Registration statement under Securities Act of 1933 |
Feb 5, 2025 | 8-K | Current Report |
Jan 21, 2025 | SCHEDULE 13G | Filing |
Dec 17, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
Dec 17, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
Dec 17, 2024 | 8-K | Current Report |